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Case presentation
A 7-year-old white boy was in apparent good health until a routine
urine dipstick test disclosed microscopic hematuria (30 red blood
cells/high-power field) and 3+ proteinuria. This persisted for 3 months
and was associated with 2 episodes of gross hematuria. He was referred
to a pediatric nephrologist at that time. Review of the family history
revealed that the patient's mother was 43 years old and had hyperten-
sion; the father, 48 years old, apparently had a history of Addison's
disease and renal calculi; two brothers, ages 18 and 22. were living and
well with no history of gross hematuria. Physical examination revealed
no abnormalities, and a normal blood pressure, 110/75 mm Hg, was
recorded. No peripheral edema was present. Examination of the urine
sediment revealed many red blood cells/high-power field, red blood cell
casts, and moderate proteinuria. Serum creatinine was 0.9 mg/dl, giving
an estimated GFR of92 ml/min/l.73 m2; serum calcium, 10.3 mg/dl: and
urine protein/creatinine ratio, 0.23.
Two months later, the patient experienced another episode of gross
hematuria. The blood pressure was 100/58 mm Hg, and the serum
creatinine had increased to 1.2 mg/dl (estimated UFR, 69 ml/min/1.73
m2). The physical examination and other laboratory studies were
otherwise unremarkable. A renal biopsy obtained at that time revealed
only minimal changes by light microscopy, but electron microscopy
disclosed mesangial electron-dense deposits, and immunofluorescence
studies showed strong mesangial deposits of IgA. A diagnosis of igA
nephropathy (Berger's disease) was made.
During the next 6 months he had 3 additional episodes of gross
hematuria but his blood pressure remained normal at 110/60 mm Hg and
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the serum creatinine fell to 0.7 mg/dl (estimated GFR, 118 mI/mm/I .73
m2). Microscopic examination of the urine disclosed no red blood cells
and trace proteinuria. Serum IgA concentration was normal (150 mg/dl).
The patient had no recurrences of gross hemattiria for the next 3
years. He then was given penicillin for an upper respiratory tract
infection. Two weeks atier starting the penicillin, the patient developed
a diffuse rash and lower-extremity purpura. arthritis of the left ankle
and knee, and abdominal pain associated with nausea and vomiting.
Physical examination revealed fading purpura over both legs and
buttocks. The arthritis of the left ankle appeared to be diminishing.
Laboratory data included: serum creatinine, t).9 mg/dl: BUN, 19 mg/dl:
hemoglobin, 15.3 g/dl; hematocrit, 46.6%: platelet count, 430,000 nim3:
and white blood cell count, 17,400 mm3. Urinalysis showed only 2 to 4
red blood cells/high-power field: a urine dipstick test disclosed trace
proteinuria. A diagnosis of Henoch-Schontein purpura was made. After
a period of observation, the patient was discharged from the hospital in
stable condition: the rash had almost completely resolved.
When the patient was seen 3 weeks later, the rash and arthritis had
disappeared. Urinalysis was negative. Physical examination and labo-
ratory studies were unremarkabte. Six weeks later he had a completely
normal physical examination. There had been no exacerbations of rash.
arthritis, or abdominal pain. Urinalysis was unremarkable except for
trace proteinuria, and the blood pressure was normal. On examination
2 months later, he had no recurrence of the purpura or other symptoms.
Physical examination and laboratory studies remained unremarkable
except for trace proteinuria.
The patient was last seen a few months ago: the physical examination
was unremarkable, as was the urinalysis. Serum creatinine was .2
mg/dl. The rash, abdominal pain, and arthritis had not reappeared.
I)iscussion
DR. FRED G. S1I.vA (Co—Director, Renal Pathology, U,tii'er—
sity of 'I'eras South western Medical Center at Dallas; Prfssor
o.t Pathology and Associate Director, Southwest Pediatric
Nephrologv Study Gi'oiip, Dallas, Texas): The patient pre-
sented today, one of a group of childi-en with IgA nephropathy
described in the initial Southwest Pediatric Nephrology Study
Group (SPNSG) report in 1982 Ill, was diagnosed as having IgA
nephropathy (Berger's disease) at the time of his initial biopsy.
However, immunofluorescence studies can demonstrate IgA in
the glomeruli in a number ofglomerulonephropathies other than
IgA nephropathy (Table I) [2]. In most of these disorders, the
intensity of IgA staining is less than the intensity of lgG. C3, or
the other immunoreactants. We will use the conventional
definition of IgA nephiopathy: the presence of dominant or
codominant mesangial IgA deposition in the glomeruli in the
absence of clinical or laboratory evidence of systemic lupus
erythematosus (SLE), Henoch-Schönlein purpura, or chronic
liver disease [2—7]. Note that the diagnosis of IgA nephropathy
requires the demonstration by immunofluorescence studies of
renal mesangial IgA deposition and that the diagnosis cannot
definitively be made on the basis of any other means (such as
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Table 1. IgA-associated glomerulopathies
Systemic lupus erythematosus
Acute glomerulonephritis
Henoch-SchOnlein purpura (anaphylactoid purpura)
Chronic liver disease
Anti-glomerular basement membrane glomerulonephritis
Membranoproliferative (mesangiocapillary) glomerulonephritis
Focal sclerosis
Minimal-change nephrotic syndrome
Crescentic glomerulonephritis
Membranous glomerulonephropathy
Others
skin biopsy, serum IgA level, or hematuria). Whether igA
nephropathy represents one disease or is a manifestation of
several diseases remains to be determined [8, 9]. The lesion
does have a variety of light microscopic patterns, ranging from
normal-appearing glomeruli, to pure mild mesangial hypercel-
lularity, to more severe patterns such as focal glomerulonephri-
tis and crescentic glomerulonephritis [10].
Despite earlier suggestions that IgA nephropathy is milder in
children than in adults, the SPNSG found that approximately
5% of children progressed to end-stage renal disease [III,
whereas the overall percentage of adults progressing to ESRD
was 10% to 20% at 10 years followup [12]. Pediatric patients
with more severe glomerular disease (that is, focal glomerulo-
nephritis) are more likely to progress to end-stage disease than
are those with mild glomerular disease [Il]. Pediatric patients
with IgA nephropathy who had essentially normal glomeruli,
such as today's patient, did not manifest progressive disease.
Our data thus suggest that the prognosis in the patient presented
today is good.
Long-term followup often generates humility in us all. De-
spite the fact that this patient was reported in 1982 as having
typical idiopathic IgA nephropathy [I], the subsequent course
has proved quite different. He developed classic signs and
symptoms of Henoch-Schönlein purpura with arthropathy, vas-
culitic rash, and evidence of preexisting renal involvement. It is
possible that IgA nephropathy is a monosymptomatic form of
Henoch-SchOnlein (anaphylactoid) purpura and that in both
conditions the mesangial and the cutaneous deposits originate
from the gastrointestinal mucosa [13, 14]. Certainly the granular
pattern of the IgA deposits suggests an immune-complex cause,
and the occurrence of the deposits in several organs (renal
mesangium, cutaneous capillaries, and capillary walls of the
jejunum) in Berger's disease and Henoch-Schönlein purpura
lends support to this theory [IS]. The study of renal biopsies by
immunofluorescence has suggested not only the immunologic
nature of IgA nephropathy and Henoch-Schonlein purpura. but
also the remarkable similarity between the renal lesions of the
two disorders. The differences between the peak age incidences
of IgA nephropathy and Henoch-Schönlein purpura (the latter
being primarily a disease of young children, and the former
being more commonly noted in adolescents and young adults)
have suggested to some clinicians, however, that these disor-
ders might be separate entities [3].
Recent articles have differed in their conclusions about the
relationship between these two conditions." Meadow and
Scott advanced the suggestion that these lesions represent
different expressions of a single disease [161. They reported
twins with IgA nephropathy; one child had classic symptoms of
Henoch-Schönlein purpura, whereas the sibling presented with
no such evidence of 'concomitant systemic disease." It is
possible that the two siblings developed two different condi-
tions at the same time, but it appeared more likely to the
authors that these were different clinical expressions of the
same disease. A number of clinicopathologic studies show the
evolution of typical IgA nephropathy into classic Henoch-
Schonlein purpura, as in today's patient [17, 18]. In some of
these studies, the lag time between the biopsy demonstrating
IgA nephropathy (in patients who appeared to have no evidence
of extrarenal disease) and the onset of the classic signs and
symptoms of Henoch-Schönlein purpura ranged from 9 months
to as long as 9 years [17].
Although Henoch-Schönlein purpura usually is a systemic
disease involving the skin, gastrointestinal tract, joints, and
kidneys, some of the features can be mild or even evanescent
and are detected only by careful inspection [3]. In some patients
the distinction between IgA nephropathy and Henoch-SchOnlein
purpura can be blurred, especially when systemic manifestations
of Henoch-Schönlein purpura are mild, and during exacerba-
tions of IgA nephropathy. Severe abdominal pain, generalized
muscle aches, and loin pain are associated with synpharyngitic
gross hematuria in a few patients with IgA nephropathy [3, 17];
episodes of synpharyngitic hematuria appear in patients with
Henoch-Schönlein purpura as well. Many patients with Henoch-
Schonlein purpura also have persistent proteinuria, microscopic
hematuria, and an active" urinary sediment many years after
the initial episode [31. Thus the clinical findings in Henoch-
Schonlein purpura and IgA nephropathy occasionally can "over-
lap."
Nakamoto and colleagues compared 205 patients who had
IgA nephropathy with 35 patients who had Henoch-Schonlein
purpura and found no differences between these two in regard
to clinical or laboratory features (except for rash, abdominal
and loin pain by definition, and degree of proteinuria) [17].
Counahan and coworkers, in a study of 45 patients with Henoch-
Schonlein purpura and 350 patients with IgA nephropathy,
found no major differences in the light-microscopic features
[19]; Nakamoto found that by light-microscopic examination,
Henoch-Schönlein purpura was more likely to be associated
with more severe glomerular involvement (with crescents. etc.)
than was IgA nephropathy, although it is well documented that
severe glonierular disease can exist in classic IgA nephropathy
[4—6, 171. Electron microscopic studies also fail to clarify any
differences between IgA nephropathy and Henoch-Schönlein
purpura [17]. although Mihatsch demonstrated more prominent
glomerular subepithelial and subendothelial deposits and a
greater degree of glomerular capillary basement membrane
change in Henoch-SchOnlein purpura than in IgA nephropathy
[20]. Glomerular mesangial deposits, however, were more
prominent in IgA nephropathy than in Henoch-Schönlein pur-
pura. Both conditions have positive IgA immunofluorescence in
the vasculitic skin lesions and in the subdermal capillaries of
normal skin [21]. Thus, although the light microscopic, immu-
nofluorescence, and electron micrographic renal changes in
these two conditions are quite similar, clinical inflammatory
changes in extrarenal blood vessels appear to be the exclusive
preserve of Henoch-SchOnlein purpura [3]. This finding sug-
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A. Is there glomerular
hypercellularity (with
closure of capillary lumens):
The true glomerulonephritides
Glomerular
hypercellularity
(usually nephritic)
Intracapillary or Extracapillary
(crescents)
escntic
G N
Diffuse or
1 1
Focal GN
(SLE, collagen-
vascular diseases,
infective eridocarditis,
etc.)
The
glomeruloriephropathies
Minimal
glomerular
hypercellularity
(usually nephrotic)
Mesangium Diffuse Segmental
normal mesangial mesangial
minimal- prominence sclerosis
change Diffuse Focal
nephrotic mesangial segmental
syndrome hypercellularity sclerosis
or or
membranous diabetic
glomerulo- nephropathy
nephropathy (EM-thick
(EM-subepithelial GBM)
deposits)
Fig. 1. Algorithm qf morphologic interpretation of glomerular patterns.
gests to some that Henoch-Schönlein purpura is a diffuse
vascular form of IgA nephropathy.
The mechanisms of glomerular injury in Henoch-Schonlein
purpura and IgA nephropathy are unclear. Circulating IgA-
containing immune complexes and high plasma levels of IgA
have been noted in both Henoch-Schönlein purpura and IgA
nephropathy 122, 23]. Habib and Cameron suggested that the
serum levels of IgA are more likely to be elevated in Henoch-
SchOnlein purpura during clinical exacerbations [241, although
the same has been noted in some cases of IgA nephropathy.
Animal models exist for IgA nephropathy 17, 251, but there are
no acceptable models thus far for Henoch-Schonlein purpura.
Whether the similarities outweigh the diflèrences between IgA
nephropathy and Henoch-Schonlein purpura depends on one's
view. Ockham's razor, the Law of Parsimony ("Entities are not
to be multiplied beyond necessity"), dictates that Henoch-
Schönlein purpura is just a more severe systemic form of IgA
nephropathy. However, most patients with IgA nephropathy do
not develop Henoch-SchOnlein purpura during long periods of
followup. Whether Henoch-Schonlein purpura is part and par-
cel of IgA nephropathy or a separate entity sharing only the
presence of the mesangial deposition of IgA will remain unclear
until the pathogenetic mechanisms of both IgA nephropathy
and Henoch-SchOnlein purpura are understood.
Morphologic classification
Classifications of pediatric renal disease (most specifically
glomerular disease) can be structured along several lines: (1)
etiologic, (2) immunologic, (3) clinical, and (4) morphologic.
Because I am a pathologist, I will order my survey of pediatric
renal disease according to an algorithm that stresses glomerular
morphology, In essence, it is the way in which most renal
pathologists arrive at a morphologic diagnosis (Fig. 1). The first
step in the interpretation of glomerular disease is determining
on thin paraffin or plastic sections whether the glomeruli are
hypercellular; normocellularity is defined by the World Health
Organization as no more than 2 cells in an individual glomerular
mesangial region, in thin 2—3 micron sections, away from the
vascular pole [261. If the hypercellularity is severe and narrows
glomerular capillaries (the morphologic definition of a glomer-
ulonephritis), one has to decide whether the hypercellularity is
within the glomerular tuft (intracapillary glomerulonephritis) or
outside the tuft in Bowman's space (extracapillary glomerulo-
nephritis). At the same time, one must decide whether the
disease affects "virtually all," "almost all," "most" of the
glomeruli (diffuse), or only some of the glomeruli studied with
light microscopy 26, 27]. The term "segmental" refers to a
disease process that affects only a portion of the glomerulus,
whereas the term "global" is used when the disease affects the
entire, or almost the entire, glomerulus, as evidenced by light
microscopy.
The classification I employ currently is neither unique nor
original; it is widely used and is based on requirements that
must be met before any histologic classification can be ac-
cepted: (I) the classification must he clinically significant, (2) it
must be easy to use and be reproducible, and (3) it must be, as
far as we know, scientifically correct. The classification I use,
like all other classifications, is neither final nor perfect, but it
or
B. Is the hypercellularity:
C. Is the hypercellularity:
(1)
(2)
Acute postinfectious
GN
Membrano-
proliferative
GN
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allows us to categorize renal involvement, correlates with the
clinical findings, and often is indicative of renal prognosis.
I now will review pediatric renal disease from this morpho-
logic perspective. I should point out that many published
studies originated from single institutions, included only a few
patients, lacked rigid histologic criteria for diagnosis, and/or do
not include data from electron microscopic or immunofluores-
cence studies. To avoid the bias that permeates such studies,
most of my comments about renal biopsy in pediatric renal
disease will be drawn from large series and, in particular, from
the results of large collaborative studies.
Some of the information that follows originated from the
Southwest Pediatric Nephrology Study Group, which was
founded in 1980 by Dr. Ronald J. Hogg, Chief of Pediatrics,
Baylor University Medical Center, in Dallas. Having observed
in the late l970s some of the geographic and fiscal constraints
that hampered the activity of the first major collaborative study
group in pediatric renal disease—the International Study of
Kidney Disease in Children (ISKDC)—Dr. Hogg saw the need
for a regional collaborative study group. The SPNSG now
involves IS medical centers, II cities, and 8 states; it involves
more than 45 clinicians and 18 pathologists. As Associate
Director of the SPNSG and on behalf of its members, I present
material that has originated from these studies. The SPNSG
clinicopathologic studies have utilized the semiquantitative
approach to the interpretation of renal biopsy introduced by Dr.
Conrad L. Pirani [281. I will not comment on several aspects of
renal biopsy in children, including the choice of biopsy needle,
localization techniques, complications, and contraindications,
which are described elsewhere by Hogg [29].
The hvpercellular glomerular diseases
Acute diffuse proliferative glomerulonephritis. Acute, diffuse
proliferative glomerulonephritis is manifested by proliferation
of native glomerular intracapillary (mostly mesangial) cells
and/or infiltration of the tuft by mononuclear cells or polymor-
phonuclear leukocytes. There is narrowing of the glomerular
capillaries and sometimes crescent formation. Electron micros-
copy usually discloses discrete 'immune-type," electron-dense
glomerular subepithelial deposits ("humps"). Immunofluores-
cent study demonstrates the typical granular glomerular capil-
lary wall deposits of IgG and C3; other immunoreactants
occasionally are present [30, 31]. In most children, acute,
diffuse proliferative glomerulonephritis is caused by a group A
beta-hemolytic streptococcal infection (of certain nephritogenic
strains), but any one of a number of infections can lead to this
pattern. Serum complement (C3) is invariably depressed in the
acute stage, and antibodies to a variety of streptococcal anti-
gens can be identified in the serum.
Children with the acute nephritic syndrome are rarely biop-
sied, because most such patients have a self-limited disease that
has a good prognosis, even when associated with widespread
crescent formation [4]. Indications for considering renal biopsy
in children with acute nephritic syndrome include: (I) persistent
gross hematuria beyond one month or persistent hypocomple-
mentemia beyond 6 weeks; (2) progressive deterioration of
glomerular filtration rate; (3) hypertension persisting beyond 2
months; (4) extrarenal manifestations of systemic disease; (5)
family history of renal disease; (6) age less than 2 years; or (7)
onset of nephritis within 48 hours of pharyngitis [29]. The most
frequent example of another disease masquerading as postinfec-
tious glomerulonephritis is membranoproliferative glomerulo-
nephritis.
Tt'Iemhranoproliferative (mesangiocapillary) glomerulonephri-
tis, type 1. Membranoproliferative glomerulonephritis (MPGN)
is defined solely on the basis of its characteristic morphologic
appearance and is one of the most common histopathologic
patterns noted in children with idiopathic nephrotic syndrome.
This type of glomerulonephritis accounted for approximately
7.5% of the pediatric patients with idiopathic nephrotic syn-
drome in the ISKDC study [32]. Most patients with this lesion
present had clinical features of nephritis in addition to heavy
proteinuria. Membranoproliferative glomerulonephritis has been
divided into different subtypes. The first, termed MPGN, type
I, features massive glomerular subendothelial deposits and was
first described in 1965 by West et al [33] and by Gotoff et al [34].
Although MPGN was initially termed "hypocomplementemic
persistent (chronic) glomerulonephritis" [331, it is now known
that a number of renal glomerular diseases (such as SLE,
postinfectious glomerulonephritis, and shunt nephritis) are as-
sociated with hypocomplementemia; morphologic characteris-
tics thus best identify this disease [351. As the name implies,
there is a membrane component, thickened glomerular capillary
walls, due to: (I) large glomerular subendothelial immune
deposits, (2) circumferential interposition of mesangial cells
between the glomerular endothelium and the glomerular base-
ment membrane, and (3) production of an inner basement
membrane-like material by the interposed mesangial cell, with
creation of classic "tram-tracking" or "reduplication" of the
glomerular basement membrane. The other part of the name
indicates the existence of diffuse intracapillary hypercellularity
within the glomerular tuft; because this hypercellularity ex-
pands the lobules, lobular accentuation often is present (hence
the old term "lobular glomerulonephritis"). Immunofluores-
cence demonstrates granular confluent capillary wall and mes-
angial deposits of C3, and frequently other immunoreactants.
Hogg has stated:
The renal biopsy has been very important in defining pediatric
patients with MPGN prior to therapy because children with MPGN
who receive high doses of daily prednisone often encounter signif-
icant problems with hypertension. It is relevant, therefore, to
seriously consider the performance of a renal biopsy in any child
with idiopathic nephrotic syndrome who has features that are
suggestive of MPGN before proceeding to a therapeutic trial with
steroids. Such features include hypocomplementemia, persistent
hematuria, hypertension or decreased renal function [29].
Although a formula has been proposed (based on clinical and
laboratory findings) to suggest the presence of MPGN [32], as
with virtually all the morphologic entities herein discussed, the
only way to absolutely determine the nature of the glomerular
disease in the individual patient is renal biopsy.
Membranoproliferative glomerulonephritis is a chronic pro-
gressive disease. In Habib's study of a large number of patients,
approximately one-fourth had died from renal disease or were
on dialysis; 11% were in chronic renal failure; 29% were
nephrotic 38% were proteinuric; and 5% were in spontaneous
remission during the followup period [36].
West et at have suggested that long-term, alternate-day
prednisone therapy successfully stabilizes the renal parenchy-
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mal damage that occurs with MPGN [37, 381. The ISKDC also
has suggested that this therapy is effective for biopsy-doc-
umented MPGN [39, 40], and other reports are forthcoming.
Other therapies such as aspirin and persantine have been
suggested, but no prospective large studies have yet been
convincing.
Dense-deposit disease (membranoproliferative glomerulone-
phritis, type II). Although often referred to as MPGN, type II,
dense-deposit disease was reported before MPGN, type I [41].
As with type-I MPGN, the clinical findings include the nephritic
and/or nephrotic syndrome, and occasionally a rapidly progres-
sive course. Although the term "type-LI MPGN" suggests that
this entity is similar to type I, the former also can have a
number of other glomerular forms visible on light microscopy.
These forms range from an almost membranous glomerulo-
nephropathy-like appearance to that of a crescentic glomerulo-
nephritis [42—44]. The distinguishing characteristic is the unique
intramembranous alteration of the glomerular basement mem-
brane. Electron microscopy reveals the abnormality to be a
dense deposit" in the lamina densa of the glomerular base-
ment membrane; immunofluorescence discloses intense gb-
merular capillary wall loop deposits of C3, properdin, and
sometimes other immunoreactants.
Dense-deposit disease, primarily a disease of children or
young adults, has been associated with a poor prognosis in most
reported series [42]. Studies have demonstrated, however, that
the prognosis for children with dense-deposit disease is not
uniform and that certain renal biopsy findings, rather than
clinical features, can be helpful in determining which patients
are more likely to develop progressive renal insufficiency [43,
441.
In the 44 children with dense-deposit disease studied by
Habib et al, the clinical features that appeared to be harbingers
of a poor prognosis included the nephrotic syndrome, macro-
scopic hematuria, initial decrease in renal function, and no
clinical remission during the disease course [421. Lamb and
colleagues also considered the nephrotic syndrome an indicator
of a poor outcome in such patients [45].
Almost one-half of the patients described by Habib et al
developed renal insufficiency; 18 progressed to end-stage renal
disease during a period of 10 years, and 10 had a rapidly
progressive course, ending in end-stage renal disease within 2
years of the clinical onset [42]. Klein et a! reported that 56% of
their patients developed end-stage renal disease within 2.9
years of clinical presentation [461. In the 16 patients studied by
the SPNSG who had dense-deposit disease, we observed a
rapid course in only 2 patients. Klein and colleagues observed
a more benign course in 5 of 18 patients during a period of II
years of followup [461; the SPNSG noted a similar relatively
benign course in 10 of our 16 patients, 6 of whom were followed
for more than 7 years (mean, 10 years) [43].
In an analysis of factors potentially responsible for the
difference in outcome, the SPNSG noted that whereas the initial
clinical and/or laboratory features were not useful indicators of
outcome, some pathologic findings on the renal biopsy did
appear to be helpful [43]. We noted that increased glomerular
lobulation, mesangial sclerosis, and hypercellularity with gb-
merular capillary loop obliteration and mesangial deposits all
were associated with a poor outcome. Sibley et al reached
similar conclusions [44]. Thus, morphologic features are not
merely the only way to make a definitive diagnosis of dense-
deposit disease in an individual patient, but also they might
determine which patient with dense-deposit disease will de-
velop end-stage renal disease.
The role of steroid therapy or "cocktails" of aspirin and
persantine in patients with dense-deposit disease (as with
MPGN, type I) remains controversial. In Habib's study, 28
patients received steroid therapy but showed no remission of
proteinuria [42]. Four of 10 of Lamb's patients developed
chronic renal failure; 9 of the 10 patients received corticosteroid
or immunosuppressive therapy or both. The authors concluded
that dense-deposit disease is largely unresponsive to conven-
tional steroid therapy [45]. However, West and colleagues have
suggested that, as in type-I MPGN, benefit may be observed in
dense-deposit disease when high-dose alternate-day steroids
are administered. Such discordances between reports might be
due to variations in the dosage of steroids used or to the
inclusion of different degrees of morphologic severity of dense-
deposit disease itself. Although most of the patients in the
SPNSG study who maintained normal renal function for long
periods had received alternate-day prednisone, and most of
those not receiving steroids did develop end-stage renal dis-
ease, no conclusions can be drawn regarding the efficacy of
such treatment in an uncontrolled short-term retrospective
study. Clearly, large-scale prospective studies on biopsy-
defined dense-deposit disease (as well as on type-I MPGN)
utilizing different therapeutic regimens need to be undertaken.
Difluse extracapillary proli.ferative glomerulonephritis (cres—
ecu tic glomerulonephritis). A rapidly progressive deterioration
of renal function constitutes one of the common reasons for
renal biopsy in children [291. Because a number of different
conditions (such as acute diffuse intracapillary proliferative
glomerulonephritis, acute tubulointerstitial disease, and the
thrombotic microangiopathies) can lead to a rapidly progressive
disease, renal biopsy is the only way to unequivocally deter-
mine the presence of crescentic glomerubonephritis in the
individual patient.
Crescentic glomerulonephritis is a pattern caused by, or
associated with, a large number of different diseases or insults.
Crescentic glomerubonephritis is variably defined by different
authors, but most require that at least one-half of the gbomeruli
contain crescents (others require that 70% to 80% of the
gbomeruli contain crescents) [4, 47]. When the SPNSG used the
50% criterion, crescentic glomerubonephritis occurred in 50
patients in association with the following: nonspecific immune-
complex disease (13 patients), SLE (9 patients), no evidence of
any immune-complex disease—idiopathic (7 patients), post-
streptococcal glomerulonephritis (6 patients), IgA nephropathy
(4 patients), Henoch-Schonlein purpura (3 patients), vasculitis
(3 patients), idiopathic crescentic g!omerulonephritis with in-
tense linear immunolluorescence staining (3 patients), and
dense-deposit disease (2 patients) [4].
The presence of extensive crescent formation in renal biopsy
specimens usually portends a poor prognosis in children, as in
adults. Some authors have suggested that the poor outcome of
these patients depends more on the percentage of gbomeruli
showing crescents than on the underlying gbomerulonephrop-
athy [48], and that when crescents affect 80% or more of the
glomeruli the prognosis is much worse than when 50% to 70% of
glomeruli are involved.
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Several studies suggest that the outcome is more influenced
by the type of underlying glomerular process than by the extent
(or percentage) of crescent formation, after at least 50% of the
glomeruli are involved [4, 49]. The significance of crescent
formation in children with poststreptococcal glomerulonephritis
remains controversial. Although some have suggested that
children with postinfectious (usually poststreptococcal) cres-
centic glomerulonephritis have a poor outcome [48], we and
others suggest that these patients have an excellent outcome
despite extensive crescent formation [4, 47, 50]. Cameron
suggests, however, that the apparent good prognosis in patients
who had poststreptococcal glomerulonephritis with extensive
crescent formation has been misleading because most of these
patients had relatively minor crescent formation [48]. In our
study, 6 patients with poststreptococcal crescentic glomerulo-
nephritis had crescents in 51, 60, 87, 90, 92, and 100% of the
glomeruli; yet all the patients at last followup (several years)
had normal, or nearly normal, glomerular filtration rates [4]. It
is true that the crescents in these patients were generally
cellular rather than flbrocellular or fibrous and that many of the
crescents were small to medium sized (that is, there were fewer
large ones). Moreover, there was little evidence of chronic
histologic glomerular or tubulointerstitial changes such as gb-
merulosclerosis or tubular atrophy/interstitial fibrosis. Never-
theless, the SPNSG report and that of Roy, Murphy, and Arant
[491 suggest that well-documented crescentic poststreptococcal
glomerulonephritis in children has an excellent clinical outcome
and that this outcome occurred despite the lack of any specific
therapy. Such patients should receive only supportive measures
to control the acute consequences of their renal insufficiency
and hypertension until the spontaneous remission occurs.
We did identify a number of other histopathologic features of
crescentic glomerulonephritis that appeared to be harbingers of
a poor prognosis [4]. These indicators included (I) the predom-
inance of large (rather than small or medium-sized) crescents,
(2) an increased frequency of fibrous changes in the crescents
(that is, fibrocellular or fibrous crescents rather than pure
cellular crescents), (3) the presence of large numbers of gaps or
focal disruptions in the lamina densa of Bowman's capsule, and
(4) the presence of glomerulosclerosis, glomerular 1gM deposi-
tion, tubular atrophy, and interstitial fibrosis. Most of these
morphologic findings probably reflect the severity of the initial
renal insult and the probable irreversibility of the morphologic
lesions.
Our review of 50 patients with crescentic glomerulonephritis
revealed a high frequency of large gaps in the basal lamina of
Bowman's capsule. Although this finding had been described
before [51], the extent of this finding in our study was surpris-
ing. The relationship between large gaps in Bowman's capsule
and a subsequent poor outcome was striking. In addition, the
correlation between the percentage of gbomeruli with large gaps
in Bowman's capsule and the presence of fibrous transforma-
tion of the glomerular crescents (that is, the presence of
fibrocellular or fibrous crescents as opposed to pure cellular
crescents) was impressive. We speculated (from these human
morphologic studies) that the strong association among the
large gaps, the presence of fibrocellular and fibrous crescents,
and a poor outcome suggested a process by which the gaps in
the Bowman's capsule might allow interstitial fibroblasts to
enter Bowman's space and render the crescents irreversible
because of the production of collagen [4]. This suggestion has
been supported by recent studies [521.
Focal glomerulonephritis. Focal glomerulonephritis by light
microscopy is a pattern of renal injury and response in which
some but not all of the glomeruli are involved, with areas of
proliferation, necrosis, or sclerosis and the consequent narrow-
ing or closure of glomerular capillaries. The term "focal" is
arbitrarily defined in some series as affecting less than 50% of
the glomeruli or 50% of the glomerular surface area; in other
series "focal" refers to less than 80% of the glomeruli [26, 27,
53]. The remaining glomeruli appear normal with light micros-
copy. This pattern is often caused by, or associated with, a
number of disease processes, such as systemic lupus erythem-
atosus, "embolic" nephritis associated with infective endocar-
ditis, polyarteritis nodosa, Wegener's granulomatosis, Henoch-
Schönlein purpura, and Goodpasture's disease (early form).
Many cases of focal gbomerulonephritis are idiopathic.
Most of the glomerular processes termed "focal" are not
truly so, being focal only at the light microscopic level. In
patients with focal glomerulonephritis in IgA nephropathy,
Henoch-Schönlein purpura, the early stages of anti-GBM-
induced glomerulonephritis, or SLE, for example, widespread
areas of diffuse glomerular deposits are visible by immunoflu-
orescence and/or electron microscopy. What is focal are the
light microscopic manifestations of the diffuse deposition of
immune and immune-like materials. True focal glomerulone-
phritis (as defined by light, electron, and immunofluorescent
microscopy, that is, no diffuse immune-complex deposition) is
found in Wegener's granulomatosis and the microscopic form of
polyarteritis nodosa. Distinguishing between a healed focal
glomerulonephritis and focal sclerosis occasionally can be
difficult, and this problem has been addressed by Whitworth et
al [54]. Pediatric SLE-related focal glomerulonephritis is dis-
cussed elsewhere [55, 56].
Glomerular capillary wall lesions associated with the
nephrotic syndrome
Minimal-change nephrotic syndrome. Most children with
idiopathic nephrotic syndrome have minimal renal histologic
abnormalities and respond to steroid therapy [57—63]. Most
have minimal-change nephrotic syndrome (also called nil dis-
ease and lipoid nephrosis). Minimal-change nephrotic syn-
drome is manifested by essentially normal-appearing glomeruli
by light microscopy, generally negative immunofluorescence,
and the ultrastructural demonstration of 'fusion" or effacement
of the gbomerular visceral epithelial cell foot processes, The
ISKDC revealed that minimal-change nephrotic syndrome was
found in 76% of nephrotic patients [62]. This study is thought to
be the best estimate of the true incidence of minimal-change
nephrotic syndrome, because it was based on renal biopsies
performed in children with idiopathic nephrotic syndrome in
whom no steroid therapy had been given. Because most chil-
dren with idiopathic nephrotic syndrome have minimal-change
nephrotic syndrome, they usually are not biopsied; rather they
are treated empirically with steroids and are biopsied only if
they fail to respond satisfactorily to steroid therapy.
In adolescents with idiopathic nephrotic syndrome, the dis-
tribution frequency of the different glomerular lesions more
closely resembles that observed in adults than that noted in
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children [64]. In our study, minimal-change nephrotic syndrome
was noted in less than one-third of biopsied adolescents [64].
Light microscopy may reveal several minor changes in what
seems to be otherwise typical minimal-change nephrotic syn-
drome (for example, mild focal and segmental mesangial hyper-
cellularity). These minor variants do not seem to affect the
patients' ability to respond to steroids, and most of these
patients appear to have a good prognosis [63]. The reader is
referred to reviews of minimal-change nephrotic syndrome [651
and familial [66] and congenital nephrotic syndrome [67].
DlfJi4se ,nesangial hypercellularity. The association of diffuse
mesangial hypercellularity and idiopathic nephrotic syndrome
was first described by Churg et al [58] and White et a! [59] in
1970. These reports and other studies demonstrated the associ-
ation between diffuse mesangial hypercellularity and idiopathic
nephrotic syndrome in from 2% to 8% of children with idio-
pathic nephrotic syndrome. This histopathologic form, thought
by some to be a variant of minimal-change nephrotic syndrome,
clinically is associated with an increased incidence of hematuria
and has been reported to have a less favorable response to
steroid therapy [68]. In the ISKDC and in the SPNSG reports,
hematuria was noted in 44% to 89% and hypertension in 9% to
46% of children with diffuse mesangial hypercellularity and
idiopathic nephrotic syndrome, respectively. These differences
in frequency might be due to the population sample or to a lack
of conformity in the criteria for histologic diagnosis and classifi-
cation of the histopathologic lesions between the study groups.
The response of children with diffuse mesangial hypercellu-
larity and idiopathic nephrotic syndrome to treatment with
steroids and/or cytotoxic agents is relatively poor when com-
pared with responses of patients with minimal-change nephrotic
syndrome. In our SPNSG study, only one-half of the 29 patients
had a complete remission of proteinuria at some stage during a
2—month course of prednisone therapy [681. The short-term
followup of the patients (mean duration, 29 months) revealed
that most of the patients (16 of 26) had no evidence of renal
failure and that only 2 had renal insufficiency. Significant
correlations were found between several renal biopsy findings
and some clinical features [68]. Increased severity of hematuria
was associated with higher grades of diffuse mesangial hyper-
cellularity (that is, 3+ severity compared with 1 + or less
severity) and a poorer initial response to steroid therapy. Initial
resistance to steroids also was seen in patients with higher
grades of diffuse mesangial hypercellularity. In most studies,
however, the outcome for children seems unrelated to the
severity of the histopathologic lesions; most reports indicate a
favorable outcome in the majority of patients.
Glomerular mesangial 1gM deposition. Ten years ago, Co-
hen, Border, and Glassock described the deposition of 1gM in
the glomerular mesangial regions in what otherwise appeared to
be idiopathic nephrotic syndrome with minimal-change ne-
phrotic syndrome [691. Since then, more than 30 reports of this
so-called '1gM nephropathy" have been published, but the
prognostic significance of the lesion continues to be controver-
sial [70]. Some investigators believe that the lesion has a
response to steroids and an outcome more akin to that of
minimal-change nephrotic syndrome, whereas others believe
that the presence of 1gM in the glomerular mesangial regions in
this setting is a harbinger of a poor response to steroids and a
poor prognosis. Some believe that "1gM nephropathy" is
actually undiagnosed focal segmental glomerulosclerosis 70].
After reviewing the literature, I find it difficult to determine
the true meaning of the finding of 1gM deposits, probably
because most of the published reports have included a number
of different types of cases with confounding variables. These
features include (1) the severity and/or distribution of 1gM, or
other glomerular features, as disclosed by light microscopy, (2)
the clinical picture, that is, nephrotic syndrome or not, (3) the
fact that children and adults are frequently considered together
in a given study, and (4) variable followup.
Although my comments are not likely to be appreciated (or
supported) by either the 'lumpers" (those who believe 1gM
nephropathy is part and parcel of minimal-change nephrotic
syndrome) or the "splitters" (those who believe it is a separate
entity), I think we just don't know what 1gM is doing in the
glomerulus and what its significance is to the patient.
Focal segmental glomerulosclerosis. Focal sclerosis can be
found in the first great combined clinicopathologic renal studies
of Volhard and Fahr in 1914, and later by Fahr in 1925, who
thought it was a degenerative form of lipoid nephrosis [711.
Cameron suggests that focal sclerosis was documented even
before that [721. Dr. Arnold Rich of Johns Hopkins suggested in
1957 that juxtamedullary glomeruli were preferentially involved
in focal sclerosis. Churg, Habib, White, and colleagues discov-
ered that it appeared to be a "marker" associated with a poor
response to steroids and a poor prognosis in patients with
idiopathic nephrotic syndrome [58, 59]. It is now accepted that
the presence of focal segmental glomerulosclerosis denotes a
high probability of steroid resistance in children with idiopathic
nephrotic syndrome and, all too often, a high risk of progression
to end-stage renal disease.
Focal sclerosis, seen in approximately 10% of children with
idiopathic nephrotic syndrome, is the glomerular lesion that
most frequently leads to progressive renal insufficiency in
children [29]. Clinical and laboratory features thought to predict
a poor outcome include hypertension [731, increased levels of
serum cholesterol or lipids [741, nephrotic syndrome [73, 75],
and hematuria [76]. Pathologic harbingers thought to suggest a
poor prognosis include mesangial hypercellularity [76, 771, the
higher percentages of global versus segmental sclerotic lesions
[78], the presence of segmental hyalinosis [79], focal sclerosis
on an initial biopsy rather than on a subsequent biopsy [73],
tubulointerstitial disease [80], or vascular disease [74]. Despite
the previous claims for the predictive importance of several
characteristics, in our multicenter study, we were unable to
identify any clinical or pathologic features of prognostic signif-
icance [81]. Children in whom focal sclerosis was documented
on the initial renal biopsy appeared to have a lesion and
prognosis similar to those with focal sclerosis identified only on
a second or subsequent biopsy [81] after an initial biopsy
showing only minimal-change nephrotic syndrome; this finding
is in discordance with the study by Cameron [73]. It is possible
that longer followup of our patients will disclose some clinical
and/or morphologic indicator of long-term prognosis.
Focal segmental glomerulosclerosis typically leads to closure
of some glomerular capillary lumina with capillary collapse.
intracapillary foam cells, and mesangial sclerosis. There also
can be regions of superimposed hyalinosis, synechiae (adhe-
sions), visceral epithelial cell caps overlying the sclerotic col-
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lapsed segment, and sometimes lifting of the visceral epithelium
off the glomerular basement membrane. Electron microscopy
shows only increased mesangial sclerosis with glomerular cap-
illary wall collapse and the usual changes noted in glomerular
visceral epithelial cells with severe proteinuria (that is, efface-
ment of foot processes, microvillous transformation, condensa-
tion of microfilaments at the base of the enlarged visceral
epithelial cells, and protein and/or lipid droplets in the visceral
epithelial cells). Immunofluorescent examination generally is
negative except for the finding of 1gM and/or C3 in the severely
sclerotic glomerular regions (probably nonspecific). Occasion-
ally, diffuse mesangial hypercellularity and/or 1gM in mesangial
areas away from the regions of segmental sclerosis can be
found, but the meaning, interpretation, and prognosis of these
findings remains controversial and unclear [70].
Me,nhranous glornerulonephropathy. Membranous glomeru-
lonephropathy is characterized by diffuse thickening of the
glomerular capillary wall with numerous subepithelial deposits
and often "spikes" of glomerular basement membrane-like
material protruding into Bowman's space from between the
deposits. Glomerular hypercellularity usually is not pronounced.
Immunofluorescence is positive along glomerular capillary walls
in a granular pattern for IgG and C3 and sometimes for other
immunoreactants [82].
Membranous glomerulonephropathy is a rare cause of idio-
pathic nephrotic syndrome in children, although it accounts for
almost 50% of the cases of idiopathic nephrotic syndrome in
adults. The ISKDC found that 1.5% of nephrotic children have
idiopathic membranous glomerulonephropathy. Other studies
report from 6% to 9%, although some studies include cases of
membranous glomeruionephropathy associated with known dis-
orders (such as SLE) [83—85]. The discrepancy in the percent-
age of membranous glomerulonephropathy in idiopathic ne-
phrotic syndrome probably reflects differences among the care
centers as well as among approaches to therapy. In our SPNSG
study of 68 children with membranous glomerulonephropathy,
this group represented 5.5% of all children biopsied who had
nephrotic syndrome in the participating centers during the
10—year study period [86]. The frequency of membranous
glomerulonephropathy in the initial SPNSG survey of adoles-
cents (ages 13 to 19 years) was 18.5% in the treated patients and
25.5% in the untreated patients. Thus, as I noted before, the
frequency of membranous glomerulonephropathy in adolescent
patients was closer to that found in adults than that in most
pediatric series.
In the majority of our patients, there was no discernible cause
for the membranous glomerulonephropathy [86]. A number of
other children, however, had membranous glomeiulonephrop-
athy in association with SLE [86] or hepatitis B [87]. A review
of the role of hepatitis B antigenemia in the pathogenesis of
membranous glomerulonephropathy can be found elsewhere
[88]. In the 68 patients with membranous glomerulonephrop-
athy accepted into the SPNSG study, 10 had clinical and
serologic evidence of SLE. 4 had persistently high ANA titers
but no other features of SLE, and 54 had no clinical evidence of
either SLE or hepatitis B-associated membranous glomerulo-
nephropathy. Our report was the first comparing the clinical
and pathologic features in children with idiopathic and SLE-
associated membranous glomerulonephropathy [86]. The most
helpful clues to the diagnosis of SLE in the SPNSG study were
a positive ANA, hypocomplementemia, the presence of diffuse
glomerular mesangial hypercellularity, and glomerular mesan-
gial and/or subendothelial electron-dense deposits. We did note
that a few patients with idiopathic membranous glomerulone-
phropathy occasionally had hypocomplementemia and glomer-
ular mesangial and/or subendothelial deposits. Whether these
patients eventually will develop clinical and laboratory evi-
dence of SLE remains to be seen. One of our patients reported
as having idiopathic rnembranous glomerulonephropathy devel-
oped overt SLE since our paper was published 2 years ago.
Other features that previously had been touted as characteristic
of SLE-associated membranous glomerulonephropathy, such
as the presence of tubulointerstitial disease and the presence of
IgA or a combination of three or more glomerular immunoreact-
ants as shown by immunofluorescence, were not found more
commonly in SLE-associated membranous glomerulonephrop-
athy than in the idiopathic variety. We found no statistical
difference between idiopathic and SLE-associated membranous
glomerulonephropathy with respect to age, race, or gender,
although the patients with SLE-associated membranous glomer-
ulonephropathy tended to be older.
As Ijust mentioned, membranous glomerulonephropathy can
precede the extrarenal manifestations of SLE in some patients,
and the interval can be as long as 4 years. Thus followup is
needed to ensure that some of the patients labeled as having
idiopathic membranous glomerulonephropathy do not in fact
have SLE [89]. Biopsies showing a membranous glomerulo-
nephropathy with glomerular endothelial myxoviral-like micro-
tubular inclusions as well as prominent glomerular subendo-
thelial and mesangial deposits suggest SLE; occasionally these
patients later develop SLE, but because SLE is at present a
diagnosis of a combination of clinical and laboratory criteria—
the modified American Rheumatology Association criteria—
[901, these morphologic findings can only suggest the possible
presence or future development of SLE.
Although an imperfect correlation exists between the age at
presentation of clinical renal disease and the morphologic stage
of idiopathic membranous glomerulonephropathy noted in the
renal biopsies in our study, younger patients tended to have
more advanced stages of membranous glomerulonephropathy
(stages III and 1V defined by electron microscopy); less severe
stages (I and II, also defined by electron microscopy) were
found to be associated with a shorter clinical duration of disease
[861. Contradictory conclusions have been drawn with respect
to the stage of disease, age at clinical onset, and degree of
proteinuria with outcome. Our data do not resolve this problem,
but our findings do support other observations that patients
with the advanced stages of membranous glomerulonephrop-
athy on electron microscopy are more likely to develop renal
failure.
Somewhat surprisingly, an analysis of the response to treat-
ment and of the latest clinical status of patients with membra-
nous glomerulonephropathy in the SPNSG study revealed no
significant differences between patients with SLE-associated
membranous glomerulonephropathy and those with the idio-
pathic form of the disease [86]. The short-term prognosis
appears good. Obviously, as in any retrospective study, the
treatment regimens were not standardized. In our SPNSG
study, patients with idiopathic rnembranous glomerulone-
phropathy receiving alternate-day prednisone appeared to have
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better preservation of GFR than did the patients receiving no
therapy; this was not statistically significant at the P < 0.01
level. The large prospective collaborative study of the effect of
alternate-day prednisone in adults with idiopathic membranous
glomerulonephropathy did show a significant preservation of
GFR but no change in proteinuria between the control and the
treatment groups [91]. In the SPNSG patients, the frequency of
proteinuria also was unchanged by the prednisone therapy. Any
conclusions drawn from retrospective studies must be viewed
with some skepticism because of the lack of standardization of
both treatment and pathologic severity of the membranous
glomerulonephropathy.
Diabetic nephropathy. Renal failure is recognized as the
leading cause of death in type-I (insulin-dependent) diabetes
mellitus. Significant renal parenchymal damage can appear
early in the course of diabetes mellitus in children [92, 931.
Silverstein and colleagues found that 3 of 12 adolescents in
whom renal biopsies were performed had clinical evidence of
renal involvement after having type-I diabetes mellitus for less
than 7 years [921. Many patients had more severe histopatho-
logic changes than would have been anticipated based on the
clinical findings.
Preliminary studies of 14 pediatric patients with diabetes
mellitus for 4 to 10 years show that diffuse diabetic glomerulo-
sclerosis (diffuse thickening of the glomerular basement mem-
brane and mesangial regions) (in II patients) and even diffuse
and nodular diabetic glomerulosclerosis (with Kimmelstiel-
Wilson mesangial nodules) (in I patient) can occur (Dr. Eileen
N. Ellis, personal communication). Three of our diabetic pa-
tients have superimposed acute postinfectious glomerulone-
phritis.
The severity and rate of renal progression sometimes is not
appreciated until extensive renal damage has occurred, because
renal biopsies are not routinely performed in most pediatric
centers caring for children with type-I diabetes mellitus. Mauer
and coworkers have suggested that the performance of renal
biopsies in patients with type-I diabetes mellitus might become
an integral component of the long-term evaluation of different
forms of therapy in adult patients [94]. Hogg has suggested that
this approach might apply to children as well [29].
Hetnolytic—uremic syndrome
Hemolytic-uremic syndrome (HUS) can lead to glomerular
and arteriolar changes that are similar, if not identical, to those
of other thrombotic microangiopathies such as postpartum
renal failure, severe pre-eclampsia, malignant hypertension,
acute scleroderma, and humoral allograti rejection. The glomer-
ular changes include thickening of the glomerular capillary
walls by swollen endocapillary (that is, mesangial and/or endo-
thelial) cells, thickening of the lamina rara interna of the
glomerular basement membrane by subendothelial electron-
lucent "fluff" with occasional librin deposition, and narrowing
of the glomerular capillary lumina creating "bloodless glomer-
uli." Some patients can exhibit thickening and/or thrombosis of
the arterioles and interlobular arteries. Cortical necrosis can
occur.
Most of the information pertaining to the renal lesions noted
in HUS in children have come from the studies by Habib and
collaborators in Paris, who performed renal biopsies in the
majority of their patients with HUS [951. These authors suggest
that the definition of the type of pathologic lesion is quite
helpful as a prognostic indicator in individual patients. Hogg
has suggested that renal morphologic changes might serve as
markers in children in whom aggressive therapeutic interven-
tion might be attempted [291.
Habib et al described three predominant renal lesions: (I)
predominant glomerular involvement by thrombotic microan-
giopathy, (2) cortical necrosis, and (3) thrombotic microangi-
opathy involving predominantly the arterioles and medium-
sized arteries. This group concluded that although these three
lesions probably were just morphologic variants of HUS, each
different pattern was associated with a marked difference in
prognosis [951. The most common pattern noted (in about 50%
of patients) was glomerular thrombotic lesions; predominantly
arteriolar/arterial lesions and cortical necrosis each were noted
in about 25% of biopsies. The authors suggested that these
variants tended to occur in patients with similar clinical find-
ings, and they suggested that the pathologic lesions rather than
the clinical features therefore provided the best prognostic
information.
Patients with either cortical necrosis or predominant glomer-
ular changes were mostly infants (less than 28 months of age);
35 of 38 infants showed one of these two changes. Of these 35
patients, 32 recovered or had only mild evidence of persisting
renal involvement [95]. Only 3 infants had the arterial form, and
all 3 died within a few weeks of the clinical onset of HUS. Of 14
older children, 10 had the arterial form, and none of the 10
developed end-stage renal disease. Four of the 14 older children
had cortical necrosis or the glomerular lesion, and all 4 recov-
ered. Habib and colleagues suggested that the different progno-
sis observed between the infants and the older children related
more to the histopathologic lesion present than to the age of the
patient. Habib's study using repeated renal biopsies also sug-
gested that the glomeruli initially involved with HUS did not
recover and progressed to sclerosis [951. The Paris group also
examined the relationship between renal biopsy and other
purported prognostic clinical and laboratory indicators and
found that the duration of anuria was closely related to the
arterial lesion noted by renal biopsy. Patients with a nondiar-
rheal prodiome tended to have the arterial thrombotic micro-
angiopathy more often than did those with the more classic
diarrheal prodrome [951.
In our SPNSG study of 220 patients with HUS, endemic and
sporadic forms of HUS shared similar clinical features and
gastrointestinal prodromal illnesses, but the sporadic form was
more frequently associated with anuria and the need for acute
dialysis [96]. It is not clear at this time whether the increase in
severity of acute renal failure in the sporadic form translates
into a greater degree of morbidity in later childhood and in
adulthood. A study of the natural history of HUS in children
revealed that 4.5% developed end-stage renal disease and 2.5%
died during the first admission [96]. An abnormal GFR at
followup did not correlate with the presence or absence of a
gastrointestinal prodrome. No significant clinical and/or labora-
tory outcome indicators were found. We have studied renal
tissues from 24 of these patients with HUS; preliminary results
confirm the presence of the three patterns described by Habib
et al, although we found some overlap among the 3 subtypes
[971.
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Renal disease in adolescents
Most previous clinicopathologic studies of renal disease have
involved either adult or pediatric patients. Because these age
groups sometimes overlap and because teenage patients have
been excluded from many series, the SPNSG followed patients
in whom the onset of clinical renal disease appeared after their
12th birthday and in whom the first renal biopsy was performed
after their 13th birthday but before age 20. The Group in toto
biopsied 312 teenage patients between 1975 and 1984 [981. The
renal biopsy diagnoses within each of the clinical presentations
(that is, nephrotic syndrome, gross hematuria, and acute renal
failure) were varied, heterogeneous, and sometimes unex-
pected. Comparison of these data with results from other large
pediatric and adult series suggests that the spectrum of 'ado-
lescent" renal diseases approaches that observed in adults,
rather than that seen in younger children [98].
We evaluated the renal biopsies of adolescent patients with
gross hematuria: 28 of these 56 patients had IgA nephropathy
[99]. The renal lesions in the other patients included minimal
glomerular changes (16%), diffuse mesangial hypercellularity
(7%), a proliferative glomerulonephritis (6%), type-I membra-
noproliferative glomerulonephritis (5%), focal sclerosis (5%),
and crescentic glomerulonephritis (4%). Many of these patients
had had previous invasive and extensive urologic and surgical
studies. The results of renal biopsy in the adolescents with SLE
[100] and idiopathic nephrotic syndrome [64] are discussed
elsewhere.
Asymptoinatic hematuria
Asymptomatic hematuria in children presents one of the most
controversial problems regarding the use of renal biopsy. The
differing diagnostic approaches and management strategies ex-
isting among nephrologists faced with this situation introduce a
major selection bias that must be recognized when interpreting
the reported frequency of histologic lesions noted on the renal
biopsy [29].
Piel and colleagues studied 61 nonuremic children with
unexplained hematuria and found that patients with renal changes
could be divided into three groups [101]. In 26 patients, the only
abnormality was attenuation of the lamina densa of the glomer-
ular basement membrane. In 18 patients, IgA nephropathy was
noted. In 17 patients, nonspecific diagnostic features were
present, and two-thirds of these biopsies were regarded as
normal [101]. In another report, about 40% of patients with
recurrent and persistent hematuria had mesangial immunoglob-
ulin deposition as the predominant feature (with IgA being the
principal immunoreactant in one-half of these) [102]. Of the 75
patients studied, 21 had essentially negative findings on immu-
nolluorescence studies, and 27 of 75 samples were typified by
only vascular deposition of C3 (thought by most to be nonspe-
cific) [102]. Pardo and coworkers, in studying 65 patients with
primary hematuria, found that almost one-half had evidence of
mesangial hypercellularity; mesangial deposits of immunoglob-
ulins and/or complement were seen in two-thirds of the speci-
mens examined [103]. The predominant immunoglobulin iden-
tified was 1gM. Electron-dense deposits were noted in only 12
of the 65 biopsies studied. No evidence of deterioration of renal
function was found in 39 of their patients followed for a median
of 4 years. Pardo thus suggested that renal biopsy probably
should not be performed in such patients, because the outcome
appears to be good [103]. Longer followup is needed to deter-
mine the ultimate outcome in these patients, and to determine
whether "benign" essential hematuria is a valid term. Because
they appear to do so well clinically, these patients tend to be
lost to followup. As a result, we are not certain what the
long-range forecast is for these patients. If more successful
therapy is developed for IgA nephropathy (and if we can
determine which of these patients to treat), the question of renal
biopsy in children with isolated hematuria is more likely to be
answered in the affirmative than it is at present. The interesting
association between idiopathic hypercalciuria and asympto-
matic gross hematuria recently has been studied by Stapleton et
al [104].
Acute tuhulointerstitial nephritis
Most reports of primary acute tubulointerstitial disease deal
with only a small number of patients. Few detailed reports of
interstitial nephritis in large numbers of children exist [105.—
107]. The spectrum of lesions comprising interstitial nephritis in
children appears to be similar to that in adults [105, 108]. The
most common finding is the presence of lymphocytes, plasma
cells, and eosinophils in the renal interstitium. Sufficiently
intense infiltration of the tubules by inflammatory cells ("tubul-
itis") and tubular degenerative changes is often present to
justify the term "tubulointerstitial nephritis."
Tubulointerstitial nephritis of acute onset in children is usu-
ally associated with drugs, such as antibiotics or anticonvul-
sants [109]. The demonstration of acute tubulointerstitial ne-
phritis in children receiving multiple medications often leads to
a difficult medical dilemma, particularly when the renal insuffi-
ciency is severe and the withdrawal of the suspect medications
is not tolerated by the patient [29]. The prognosis of tubuloin-
terstitial nephritis in children appears to be good, although the
small number of reports precludes a definitive statement. The
usual treatment is withdrawal of the drug (if known and if
possible) and administration of either daily oral prednisone or
high-dose intravenous "boluses" of prednisone for a short
period. Although no large controlled trials have demonstrated
the efficacy of steroid therapy, anecdotal reports suggest ben-
efit.
In 23 children with interstitial nephritis studied by the SPNSG,
16 patients had an acute clinical Onset of interstitial nephritis
[107]. Eight cases were drug-related, 2 were due to infections,
and the remaining 6 were idiopathic. The 7 patients with chronic
interstitial nephritis (that is, longstanding clinical disease) had a
variety of congenital renal diseases ranging from cystic to
metabolic in nature. Renal outcome appeared to be more
closely related to the cause of interstitial nephritis (that is, drug-
versus non-drug-related) than to the severity of the interstitial
inflammation or the presence or absence of tubular basement
membrane breaks or gaps. This association probably is due to
the physician's ability to selectively withdraw the offending
agent and thus to allow restoration of normal renal structure
and function.
Summary
I have given a brief overview of the morphologic basis of
renal disease in children. Obviously I have been unable to
include all the important and well-done studies of various
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conditions, which together cover the entire spectrum of pedi-
atric renal disease. It is evident from the many studies that the
renal biopsy has been, is, and will be quite helpful in elucidating
the histologic pattern and severity of injury in the child with
clinical evidence of renal disease. As therapy becomes more
effective for renal diseases known to cause progressive renal
insufficiency, the impact of the renal biopsy will become even
greater.
Because of the frequent discordance between clinical labora-
tory findings and renal histologic severity, an initial or baseline
biopsy is often the only way to stage the alterations in renal
structure. Present tests of renal function are imperfect and are
insensitive parameters of insidious and progressive renal dis-
ease. The capacity of the kidney to compensate for nephron
loss by hypertrophy and modification of the remaining nephrons
can mask progressive renal disease and thus impair our ability
to detect meaningful differences in therapeutic results. A re-
peated biopsy or "second look" allows detailed comparison
and study of the effects of various therapeutic regimens on the
renal disease process. Continued, detailed clinical-morphologic
correlations and studies using improved techniques hopefully
will provide us with better profiles or predictors of the type,
severity, and pathogenesis of the renal disease in the individual
patient. Determination of the histologic pattern by renal biopsy
at present remains one of the, if not the, most important and
reliable prognostic indicators in the individual patient and
allows us a unique look at the host response to the varying types
of injuries leading to pediatric renal disease.
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Given the wealth
of data your collaborative group has collected to date, do your
clinicians believe that their ability to prevent end-stage renal
disease has improved? My understanding is that only one child
per million of the pediatric population develops end-stage renal
disease annually. How have your collaborative studies had an
impact on that incidence?
DR. SILvA: Our studies have not prevented end-stage renal
disease, but 1 think that our close association over 7 years has
helped hone our talents ir terms of conducting clinical and
morphologic studies. We have addressed whether we should do
prospective therapy-related trials, but at present there is no
really effective therapy for most renal diseases. In the future,
when we have therapy that is potentially effective, clinical and
renal biopsy data will be important in defining which patients to
treat.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center): I believe
renal biopsy is an extremely valuable tool in the investigation of
renal diseases, but I think that many more renal biopsies are
done than are required for decisions regarding therapy. One
might argue that the biopsy provides prognostic information,
but in renal disease in children, the prognosis typically is so
favorable that histologic confirmation is superfluous, What is
your opinion of the value of renal biopsy in the clinical
management of the pediatric patient with renal disease?
DR. SILvA: Several articles, one by Hogg for example,
suggest that renal biopsy can be important if used in a selective
fashion. We generally don't biopsy patients with acute nephritic
syndrome if they seem to be postinfectious, and we generally
don't biopsy pediatric patients with idiopathic nephrotic syn-
drome unless they don't respond to steroids. We are restricting
our use of renal biopsy more and more. If a patient does not
have a "classic" example of a particular disorder, the only way
to determine what lesion that patient has is to perform the
biopsy. Obviously the pros and cons of renal biopsy have to be
weighed. But, for example, in the pediatric group, certain
regimens of steroids given to treat certain types of glomerular
nephropathies can induce severe hypertension. So it is impor-
tant in many cases to know what lesion the patient has. In
lupus, some clinicians believe that therapy should be tailored to
the biopsy findings in adults and children. However, I think that
the indications for biopsy are becoming more and more limited,
and that patients are being biopsied only if they don't fall into
the classic clinical syndromes, especially if therapy depends on
the findings. The real advent, the new coming of the renal
biopsy, will occur when we develop better therapies for gb-
merular diseases.
DR. HARRINGTON: In my experience and that of most ne-
phrobogists, the incidence of acute postinfectious nephritis has
receded dramatically in the last 25 years. Yet you described a
recent mini-epidemic of acute gbomerular disease due to hepa-
titis B. To what do you attribute this phenomenon?
DR. SILvA: In some countries there seems to be a strong
association between hepatitis B and membranous glomerubo-
nephropathy. However, the 16 or 17 children with membranous
glomerulonephropathy and hepatitis that I alluded to were not
all from one city, but rather were from the medical centers in
the SPNSG. Dr. Stapleton noted that many children whom we
are now seeing with membranous glomerulonephropathy and
idiopathic nephrotic syndrome have serologic evidence of hep-
atitis B. We haven't been able to perform sophisticated immu-
nologic studies to detect the antigen and/or the antibody be-
cause these are retrospective studies and we don't have a lot of
frozen tissue; so I don't know which came first, the hepatitis or
the membranous glomerulonephropathy.
DR. PAUL KURTIN (Chief Division of Nephrology, New
England Medical Center): I might add that at New York
University, we saw 4 patients, 2 children and 2 adults from
Indochina, with hepatitis B-associated membranous nephrop-
athy (Gallo G, personal communication).
DR. MICHAEL P. MADAIO (Division of Nephrology, New
England Medical Center): Would you comment on the associ-
ation of hematuria with gbomerular C3 deposition [110, 111]?
DR. SILvA: We haven't specifically looked at that. There are
several early studies on renal biopsies from patients with the
syndrome of isolated or "essential" hematuria in which the
relatively normal-appearing glomeruli contain immunoreactant
material in their mesangial regions [103, 112, 1131. In most of
these, the C3 is associated with either IgG or 1gM, although an
occasional patient had isolated C3. The meaning of this im-
munoreactant material is unclear; most of these patients appear
to have a good prognosis. I have no experience with isolated C3
in this syndrome, but we not infrequently see C3 in arteries and
arterioles or regions of glomerubosclerosis, and many physi-
cians believe that this is an entirely nonspecific finding. I do not
think that it is a separate "entity" at this time. I'm having
enough trouble trying to figure out whether 1gM nephropathy
and Clq nephropathy are separable diseases! Only time will tell.
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DR. NICOLAOS E. MADIAS (Chief Dicision of Nephrologv,
Neu' England Medical Center): Do you recognize type—Ill
membranoproliferative glomerulonephritis as a distinct clinico-
pathologic entity?
DR. SILvA: I think it is appropriate to first ask which type-Ill
we are talking about, that is. the type-Ill of Burkholder [114,
115], the type-Ill of Strife [116], or the type-Ill of Klein [46]:
three or four variants of membranoproliferative glomerulone-
phritis variously are described as type-Ill membranoprolifera-
tive glomerulonephritis. I presume that you are referring to the
type-Ill MPGN reported by Strife and coworkers [116]. We
have not yet reviewed our experience with that group of
patients. When we looked at the SPNSG patients with mem-
branoproliferative glomerulonephritis, we delayed addressing
the type-Ill patients because we had much more difficulty
classifying those patients than we did classifying patients whose
biopsies revealed type-I or -II membranoproliferative glomeru-
lonephritis.
DR. JOHN H ERRI N (Chief Pediatric Nephrology. Massachi,-
zeus General Hospital, Boston): Of the studies that your group
has performed retrospectively, have many patients been prese-
lected by being referred for biopsy? How do you defend your
retrospective studies, and are you carrying out prospective
studies as well?
DR. SIlvA: In all of our retrospective studies, we are dealing
with selection biases. Any time a patient has a renal biopsy, the
patient has gone through approximately seven selection or
entry biases before a definitive tissue diagnosis can be made.
First, the patient has to be perceived as being sick. Second, the
patient has to be seen by a doctor. Third, the doctor has to
decide that the problem is serious enough to be reviewed by a
nephrologist. Fourth, the nephro!ogist decides that a biopsy is
appropriate and suggests this to the patient. Fifth, the patient
decides that there should be a renal biopsy. Sixth, the nephrolo-
gist must obtain adequate renal tissue, and, finally the pathol-
ogist must prepare the tissue in an appropriate manner to make
the diagnosis. A number of selection criteria are involved in
determining which biopsies have been reviewed in our studies.
However, we believe that because so many different regions,
states, cities, medical centers, and physicians are represented
in our studies, the conclusions are more likely to represent
what's going on in the United States than are study results
emanating from a single center. We agree that prospective
studies are needed, however. For example, we have several
prospective ongoing studies, such as the study of the prognosis
of young children who have mild to moderate degrees of
vesicoureteral reflux.
DR. KASSIRER: I suspect there will be a problem carrying out
prospective studies of renal diseases in children. To perform an
adequate prospective study, the disease you are studying has to
have a fair number of bad outcomes. In children, because the
outcome is good in most patients, one would have to recruit an
enormous population of patients to get sufficient bad outcomes
to count. Even in adult renal disease, the number of prospective
controlled studies with definitive outcomes is small. Alfred
Steinberg expressed his frustration dramatically about such
studies of lupus nephritis in these pages recently [117].
DR. SILvA: I agree that, in many children, renal diseases
don't have bad outcomes. However, there are some diseases in
which the outcome is not good, such as crescentic glomerulo-
nephritis or focal sclerosis. I also think the possibility exists
that, as we follow many of the patients with renal disease for a
longer period, a larger proportion of them will succumb to
end-stage renal disease. A few patients do have a poor out-
come, and for those patients we need improved therapy. We
need to establish collaborative studies to evaluate therapies as
they are developed.
DR. MADIAs: What are your thoughts about the striking
difference in the frequency distribution of various glomerular
diseases between children and adults?
DR. SILVA: Evaluating the incidence of different patterns and
levels of severity in glomerular diseases in children and adults is
a problem, because the adults and children are seen by different
clinicians who have different biases as to who undergoes
biopsy. There is a difference in renal biopsy findings within
certain clinical syndromes, however. For example, whereas
adults with idiopathic nephrotic syndrome often have membra-
nous glomerulonephropathy, the majority of children tend to
have minimal-change disease. I don't know why this is the case.
I think that we have to learn more about the mechanisms and
the pathogenesis underlying these glomerular injuries before we
can define why age-specific differences occur.
DR. KURTIN: Drs. Habib and Levy reported that patients
with the heniolytic-uremic syndrome who have primarily arte-
rial lesions have a worse renal and overall prognosis than do
patients with glomerular lesions [951. Has that been your finding
also? Do these patients have diffuse arterial lesions elsewhere,
for example, in the central nervous system?
DR. SILvA: About 9 autopsy cases of hemolytic-uremic
syndrome are being analyzed by Drs. Craig Argyle, Ted Pysher,
and other members of the SPNSG [1181. We have seen some
evidence of vasculopathy in the brains, small intestines, and
other viscera of the patients, but generally these changes are
not marked.
DR. KURTIN: In patients with IgA nephropathy, do you think
the timing of the biopsy is important? A recent paper from
Japan reported 200 patients identified in school screening
programs as having proteinuria with or without hematuria [1191.
Their outcomes were much better than were those of patients
studied by the SPNSG; in the latter study, 27% of patients
developed end-stage renal disease [II]. The majority of the
Japanese children were asymptomatic at the time of the biopsy.
Is the disease different in Japan and the United States, or has a
screening program identified patients at an earlier time in their
course?
DR. SILvA: In our SPNSG experience, the 9 of 177 children
that progressed to end-stage renal disease (that is, 5% overall)
had diffuse glomerulonephritis or focal glomerulonephritis on
their first biopsy; 27% of our IgA patients with severe glomer-
ular changes (that is, focal glomerulonephritis) progressed to
end-stage renal disease [II]. In Yoshikawa's study, 5% of the
children had chronic renal failure [119]. In our initial study in
1982, we looked at the timing of the clinical onset versus the
time of the biopsy, and we found no relationship between the
clinical duration of renal disease and the type of lesion apparent
on the renal biopsy [2].
DR. ANDREW LEVEY (Division of Nephrology, New England
Medical Center): I have two questions about IgA nephropathy.
First, are the pathologic features of the familial disease that has
been identified in eastern Tennessee similar to the sporadic
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cases that you have studied? Second, do you know of studies of
renal biopsy in adults who had Henoch-SchOnlein purpura in
childhood and who have no or only minimal abnormalities of
the urinary sediment now? Specifically, do they still have
glomerular IgA deposits?
DR. SILVA: In response to your first question, we have not
analyzed the familial cases specifically to see whether they can
be separated from the overall group, but I haven't noticed
striking differences in the biopsies from Tennessee or Kentucky
versus those from other areas. We have wondered whether the
focal and segmental glomerular basement membrane thinning,
splitting, and splintering we noted in patients with otherwise
typical IgA nephropathy was more commonly present in the
familial cases of IgA nephropathy, but we have not yet studied
that. I don't think so, however, because we found this basement
membrane alteration in about one-third of our 177 patients with
IgA nephropathy.
The second question relates to loss of mesangial IgA. To my
knowledge there are rio reports of patients who had Henoch-
SchOnlein purpura in childhood and in whom renal biopsies
demonstrate no mesangial IgA in adult life. However, at least 3
patients have been reported in whom IgA was present in the
first biopsy specimens and then absent when the biopsies were
repeated. Bergstein reported on one child whose renal biopsy
showed mild changes, but in whom IgA was present. After 45
days, another biopsy disclosed no IgA [1201. Nakamoto de-
scribed 2 patients with membranoproliferative glomerulone-
phritis in whom IgA was present but was absent in a subsequent
biopsy [17]. We have not observed this phenomenon, and I
don't think it's common, but it can happen occasionally. That
raises a question: if essential hematuria is present, but IgA is
not, does that mean that the IgA was there initially and now it's
gone? I don't think the phenomenon is common.
DR. JAMES STROM (Chief of Nephrology, St. Elizabeth's
Hospital, Boston): Dr. Silva, have you seen teenagers who
appear to have idiopathic nephrotic syndrome due to membra-
nous nephropathy but who demonstrate mesangial deposits
without lupus? Do you have followup data on whether your
patients have developed lupus?
DR. STLVA: One of our initial 50 patients with idiopathic
membranous glomerulonephropathy subsequently developed
overt SLE; that transition is well described. There is certainly
difficulty in deciding what to do with a case of otherwise
idiopathic membranous glomerulonephropathy when you find
glomerular mesangial and/or subendothelial deposits. Honig
and other authors have found mesangial deposits in otherwise-
idiopathic membranous glomerulonephropathy [121, 122]. So it
can happen occasionally. Again I would submit to you that SLE
is a clinical diagnosis. If! see glomerular mesangial deposits or
subendothelial deposits I can suggest that the patient might
develop lupus, but you are not as a clinician going to accept my
diagnosis; you are going to follow the patient and watch for
lupus. There is nothing I can see on renal biopsy, including
hematoxyphjl bodies, that will tell me unequivocally that I am
dealing with lupus membranous glomerulonephropathy in that
patient.
DR. LEVEY: Are any new facts available on familial nephrotic
syndrome?
DR. SILvA: I don't have any personal experience with familial
nephrotic syndrome, but recent papers on the subject have
appeared [123—1251.
DR. MADIAS: Have you performed studies addressing the
issue of a particular antigenic defect in the glomerular basement
membrane of patients with Alport's nephropathy?
DR. SILvA: McCoy et al [126] and others [127] have shown
that the glomerular basement membrane (GBM) in Alport's
hereditary nephropathy often lacks an antigen present in normal
GBM and that the absent antigen is related to the nephritogenic
antigen of Goodpasture's disease. This Goodpasture antigen
has been localized by Weislander et al [128, 1291 to a mono-
meric polypeptide in the noncollagenous globular domain of
GBM type-IV collagen. We haven't specifically studied that
syndrome yet.
DR. HARRJNGTON: Would you comment on the incidence of
anti-GBM disease in patients with Alport's syndrome who
receive a renal transplant?
DR. SILvA: It was deduced that patients with Alport's syn-
drome who receive renal allograft transplantation might de-
velop circulating anti-GBM antibodies and glomerular disease.
Interestingly, that complication of renal transplantation in Alport's
syndrome, although described [126, 130, 131], is less common,
thus far, than one would have suspected. This subject is treated
in a review by Bernstein [132].
Another point I'd like to make is that I think that renal
transplantation is sometimes inadvertently a great experiment
in nature. It may give us some clues in the pathogenesis of IgA
nephropathy, diabetic nephropathy, and focal sclerosis, but one
of the problems is that frequently we don't know the cause of
the initial native renal disease. Also, many things can happen to
the allografted kidney: some are due to rejection, some to
recurrence, and some to ischemia, etc.; in a transplant it is hard
to always know what mechanisms are responsible for the
alterations. I take issue with some studies; what is called
recurrent HUS, recurrent scieroderma, and recurrent Alport's
in many cases really relates to the glomerular changes that
occur due to allograft rejection. It's very difficult to distinguish
the causes of renal disease. However, we have no direct
experience with renal transplantation in patients with Alport's
syndrome.
DR. MADIAs: Is the renal prognosis of the hepatitis B-
associated membranous nephropathy substantially different from
that of the idiopathic type?
DR. SILvA: We don't have follow up yet on the majority of
those patients. However, the one patient with a long follow up
has developed end-stage renal disease. We need to follow the
rest of the patients longer; hopefully we will be able to do that.
Other authors have found that the prognosis of children with
hepatitis B-associated membranous glomerulonephropathy is
good, but this also applies to studies of idiopathic membranous
glomerulonephropathy in childhood.
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